General Information
Drug ID
DR00454
Drug Name
Sunitinib
Synonyms
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; KS-5022; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; PDGF TK antagonist; SU-11248J; SU-12662; SU11248; Su-011248; Sunitanib; Sunitinib (INN); Sunitinib (Pan-TK inhibitor); Sunitinib (free base); Sunitinibum; Sutent (TN)
Drug Type
Small molecular drug
Indication Advanced renal cell carcinoma [ICD11: 2C90] Approved [1]
Imatinib-resistant gastrointestinal stromal tumor [ICD11: 2B5B] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
3D MOL 2D MOL
Formula
C22H27FN4O2
Canonical SMILES
CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C
InChI
InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
InChIKey
WINHZLLDWRZWRT-ATVHPVEESA-N
CAS Number
CAS 557795-19-4
Pharmaceutical Properties Molecular Weight 398.5 Topological Polar Surface Area 77.2
Heavy Atom Count 29 Rotatable Bond Count 7
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 4
XLogP
2.6
PubChem CID
5329102
PubChem SID
103175813 , 104178853 , 104223163 , 11061329 , 113911638 , 118049563 , 118855335 , 124893175 , 124893176 , 126663102 , 134222706 , 134337335 , 134339174 , 135236614 , 136367772 , 137001819 , 137255559 , 137255561 , 140170598 , 14720359 , 14830382 , 152047612 , 160964598 , 162012027 , 162184461 , 163371066 , 163395369 , 164045165 , 164825281 , 164825282 , 172085035 , 172091423 , 172919594 , 176484660 , 176485072 , 26675759 , 26758053 , 39301727 , 46507140 , 50070562 , 50071184 , 50100120 , 57361294 , 8034462 , 80856906 , 85171053 , 91148451 , 93581003 , 96025237 , 99443888
ChEBI ID
ChEBI:38940
TTD Drug ID
D0R0MW
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [3]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [3]
P-GP Transporter Info P-glycoprotein 1 Substrate [4]
RALBP1 Transporter Info RalBP1-associated Eps domain-containing protein 2 Substrate [5]
Drug-Transporter Activity Data
Drug-Transporter Activity Data RALBP1 Transporter Info Km = 7.2 microM Human kidney cancer cells (Caki-2)-RALBP1 [5]
References
1 Sunitinib malate was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011 Apr 4;8(2):571-82.
3 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
4 Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9.
5 Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.